PriceTargets.com logo

Lexicon Pharmaceuticals - LXRX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $15.00
  • Forecasted Upside: 527.62%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$2.39 As of 02/6/2023 01:00 AM ET
▲ +0.03 (1.27%)

This chart shows the closing price for LXRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Lexicon Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LXRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LXRX

Analyst Price Target is $15.00
▲ +527.62% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Lexicon Pharmaceuticals in the last 3 months. The average price target is $15.00, with a high forecast of $20.00 and a low forecast of $10.00. The average price target represents a 527.62% upside from the last price of $2.39.

This chart shows the closing price for LXRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Lexicon Pharmaceuticals. This rating has held steady since January 2022, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
8/16/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
11/14/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/12/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/13/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/11/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/9/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/8/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/7/2023

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/12/2022Piper SandlerInitiated CoverageOverweight$10.00Low
7/1/2022CitigroupBoost TargetBuy$18.00 ➝ $20.00Low
8/30/2021CitigroupBoost TargetBuy$13.00 ➝ $20.00High
1/29/2021WedbushDowngradeOutperform ➝ Neutral$2.00 ➝ $8.00Low
1/29/2021JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$7.00Low
1/15/2021G.ResearchDowngradeBuy ➝ HoldN/A
1/15/2021CitigroupBoost Target$6.00 ➝ $13.00Low
1/15/2021GabelliDowngradeBuy ➝ HoldHigh
1/14/2021Smith Barney CitigroupBoost Target$6.00 ➝ $13.00High
12/8/2020Smith Barney CitigroupUpgradeNeutral ➝ BuyHigh
11/18/2020G.ResearchUpgradeHold ➝ BuyLow
11/18/2020GabelliUpgradeHold ➝ BuyHigh
10/14/2020JPMorgan Chase & Co.Initiated CoverageUnderweightMedium
8/3/2020WedbushReiterated RatingBuy$3.00Low
4/28/2020WedbushReiterated RatingBuy$9.00High
4/28/2020CitigroupLower TargetNeutral$2.30 ➝ $2.10High
4/27/2020Needham & Company LLCReiterated RatingHoldHigh
3/23/2020WedbushReiterated RatingBuy$10.00High
3/15/2020WedbushReiterated RatingBuy$13.00Medium
1/23/2020WedbushReiterated RatingBuy$17.00High
12/22/2019WedbushReiterated RatingBuy$17.00Low
12/11/2019G.ResearchDowngradeBuy ➝ HoldLow
12/11/2019GabelliDowngradeBuy ➝ HoldLow
12/2/2019WedbushReiterated RatingBuy$17.00Medium
11/13/2019WedbushReiterated RatingBuy$17.00Medium
11/8/2019CitigroupDowngradeBuy ➝ Neutral$3.00 ➝ $4.00High
10/4/2019WedbushReiterated RatingBuy$17.00Medium
9/11/2019G.ResearchUpgradeHold ➝ BuyN/A
9/11/2019GabelliUpgradeHold ➝ Buy$3.00High
8/1/2019WedbushReiterated RatingOutperform$35.00 ➝ $17.00Low
7/30/2019CitigroupLower TargetBuy$15.00 ➝ $3.00Low
7/29/2019Stifel NicolausDowngradeBuy ➝ Hold$10.00 ➝ $4.00High
6/11/2019WedbushSet TargetBuy$35.00High
6/3/2019WedbushReiterated RatingBuy$35.00Medium
5/2/2019Needham & Company LLCReiterated RatingHoldLow
4/29/2019WedbushReiterated RatingOutperform$34.00 ➝ $35.00High
3/25/2019GabelliUpgradeSell ➝ HoldHigh
3/25/2019Stifel NicolausLower TargetBuy$14.00 ➝ $10.00High
3/25/2019Needham & Company LLCReiterated RatingHoldHigh
3/13/2019GabelliDowngradeHold ➝ SellHigh
3/4/2019WedbushBoost TargetOutperform$36.00 ➝ $38.00Medium
1/22/2019WedbushSet TargetOutperform$42.00 ➝ $36.00High
1/22/2019CitigroupReiterated RatingBuy$14.00High
11/2/2018GabelliReiterated RatingHoldMedium
11/2/2018CowenReiterated RatingHoldMedium
11/2/2018CitigroupLower TargetBuy ➝ Buy$27.00 ➝ $26.00Low
7/31/2018Stifel NicolausReiterated RatingBuy ➝ Buy$24.00 ➝ $23.00High
7/30/2018Needham & Company LLCReiterated RatingHoldHigh
6/25/2018Needham & Company LLCReiterated RatingHoldMedium
6/18/2018WedbushReiterated RatingBuy$42.00Low
5/22/2018WedbushReiterated RatingOutperform$42.00 ➝ $40.00High
5/4/2018CitigroupLower TargetBuy ➝ Buy$28.00 ➝ $27.00Medium
5/4/2018Stifel NicolausLower TargetBuy ➝ Buy$25.00 ➝ $24.00High
4/16/2018WedbushBoost TargetOutperform ➝ Outperform$38.00 ➝ $40.00Medium
2/23/2018Needham & Company LLCDowngradeBuy ➝ HoldHigh
2/14/2018JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$15.00 ➝ $10.00High
(Data available from 2/7/2018 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
7/11/2022
  • 5 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
8/10/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/9/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
Mentions as of
10/9/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Mentions as of
11/8/2022
  • 0 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Mentions as of
12/8/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
1/7/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/6/2023

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Lexicon Pharmaceuticals logo
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.
Read More

Today's Range

Now: $2.39
Low: $2.31
High: $2.45

50 Day Range

MA: $2.13
Low: $1.80
High: $2.46

52 Week Range

Now: $2.39
Low: $1.31
High: $3.48

Volume

298,497 shs

Average Volume

319,503 shs

Market Capitalization

$451.06 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.38

Frequently Asked Questions

What sell-side analysts currently cover shares of Lexicon Pharmaceuticals?

The following Wall Street sell-side analysts have issued stock ratings on Lexicon Pharmaceuticals in the last twelve months: Citigroup Inc., Piper Sandler, and StockNews.com.
View the latest analyst ratings for LXRX.

What is the current price target for Lexicon Pharmaceuticals?

2 Wall Street analysts have set twelve-month price targets for Lexicon Pharmaceuticals in the last year. Their average twelve-month price target is $15.00, suggesting a possible upside of 527.6%. Citigroup Inc. has the highest price target set, predicting LXRX will reach $20.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $10.00 for Lexicon Pharmaceuticals in the next year.
View the latest price targets for LXRX.

What is the current consensus analyst rating for Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LXRX will outperform the market and that investors should add to their positions of Lexicon Pharmaceuticals.
View the latest ratings for LXRX.

What other companies compete with Lexicon Pharmaceuticals?

Other companies that are similar to Lexicon Pharmaceuticals include Vanda Pharmaceuticals, AVEO Pharmaceuticals, Rigel Pharmaceuticals, XOMA and Emergent BioSolutions. Learn More about companies similar to Lexicon Pharmaceuticals.

How do I contact Lexicon Pharmaceuticals' investor relations team?

Lexicon Pharmaceuticals' physical mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The biopharmaceutical company's listed phone number is (281) 863-3000 and its investor relations email address is [email protected] The official website for Lexicon Pharmaceuticals is www.lexpharma.com. Learn More about contacing Lexicon Pharmaceuticals investor relations.